Komori
KYORIN Pharmaceutical (4569) · InitiativeFirst stated

Expiry of the Gatifloxacin Ophthalmic Solution Out-Licensing Agreement

First written in FY2022-Q1. . Latest entry: FY2022-Q1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Expiry of the Gatifloxacin Ophthalmic Solution Out-Licensing AgreementA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q1First statedAnnual report

    「Out-licensing to a foreign company; contracting company: KYORIN Pharmaceutical Co.,Ltd. (consolidated subsidiary); product: gatifloxacin ophthalmic solution; counterparty: Allergan; country: United States; consideration: upfront fee and royalties at a specified rate; contract year: 2000; term: the longer of the expiration of the relevant patents or 15 years from the contract date.」

    The out-licensing agreement for gatifloxacin ophthalmic solution with Allergan ended upon expiration of its term.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.